These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28162270)

  • 1. Biochemical And Tumorigenic Effects Of Redox Modification Of Ras-G12c By Nitric Oxide.
    Crowe M
    Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional analysis of a mutant Ras protein that is insensitive to nitric oxide activation.
    Mott HR; Carpenter JW; Campbell SL
    Biochemistry; 1997 Mar; 36(12):3640-4. PubMed ID: 9132016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-nitrosoglutathione and endothelial nitric oxide synthase-derived nitric oxide regulate compartmentalized ras S-nitrosylation and stimulate cell proliferation.
    Batista WL; Ogata FT; Curcio MF; Miguel RB; Arai RJ; Matsuo AL; Moraes MS; Stern A; Monteiro HP
    Antioxid Redox Signal; 2013 Jan; 18(3):221-38. PubMed ID: 22894707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition.
    Huynh MV; Parsonage D; Forshaw TE; Chirasani VR; Hobbs GA; Wu H; Lee J; Furdui CM; Poole LB; Campbell SL
    J Biol Chem; 2022 Aug; 298(8):102186. PubMed ID: 35753348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
    Counter C
    Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour maintenance is mediated by eNOS.
    Lim KH; Ancrile BB; Kashatus DF; Counter CM
    Nature; 2008 Apr; 452(7187):646-9. PubMed ID: 18344980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
    Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR
    Sharma AK; Lee SJ; Rigby AC; Townson SA
    Biomol NMR Assign; 2018 Oct; 12(2):269-272. PubMed ID: 29721757
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Pálfy G; Vida I; Perczel A
    Biomol NMR Assign; 2020 Apr; 14(1):1-7. PubMed ID: 31468366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteine-based regulation of redox-sensitive Ras small GTPases.
    Messina S; De Simone G; Ascenzi P
    Redox Biol; 2019 Sep; 26():101282. PubMed ID: 31386964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
    Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
    Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of p21Ras S-nitrosylation and kinetics of nitric oxide-mediated guanine nucleotide exchange.
    Heo J; Campbell SL
    Biochemistry; 2004 Mar; 43(8):2314-22. PubMed ID: 14979728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of brain glutamate metabolism by nitric oxide and S-nitrosylation.
    Raju K; Doulias PT; Evans P; Krizman EN; Jackson JG; Horyn O; Daikhin Y; Nissim I; Yudkoff M; Nissim I; Sharp KA; Robinson MB; Ischiropoulos H
    Sci Signal; 2015 Jul; 8(384):ra68. PubMed ID: 26152695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
    Huynh MV; Campbell SL
    Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers.
    Stalnecker CA; Der CJ
    Sci Signal; 2020 Mar; 13(624):. PubMed ID: 32209699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial Nitric Oxide Synthase-Derived Nitric Oxide Prevents Dihydrofolate Reductase Degradation via Promoting S-Nitrosylation.
    Cai Z; Lu Q; Ding Y; Wang Q; Xiao L; Song P; Zou MH
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2366-73. PubMed ID: 26381869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide cell signaling: S-nitrosation of Ras superfamily GTPases.
    Raines KW; Bonini MG; Campbell SL
    Cardiovasc Res; 2007 Jul; 75(2):229-39. PubMed ID: 17559822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PKA-mediated phosphorylation of Dexras1 suppresses iron trafficking by inhibiting S-nitrosylation.
    Chen Y; Mathias L; Falero-Perez JM; Kim SF
    FEBS Lett; 2015 Oct; 589(20 Pt B):3212-9. PubMed ID: 26358293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.